Recently medicinal cannabis has been at the forefront of media attention in the...
- EMA issues positive opinion on biomarker for Parkinson’s trials
- New drugs and therapeutic options help the immune system fight cancer
- May’s top news stories
- US biosimilar setbacks highlight difficulty of cost-effective development
- POINT trial may increase clopidogrel use in secondary ischemic stroke prevention
Libtayo (cemiplimab-rwlc) for the Treatment of CSCC
Libtayo (cemiplimab-rwlc) is a fully human monoclonal antibody indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients that are not eligible to undergo curative surgery or radiation therapy.
Quick and Flexible Elemental Screening with Omnian
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
September’s top news stories
Emerald Health Pharmaceuticals (EHP) started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma, and Ra Pharmaceuticals reported positive data from the Phase lb trial examining the pharmacokinetic (PK) of zilucoplan (RA101495 SC) to treat patients with renal impairment. Drugdevelopment-technology.com wraps up the key news stories from September 2018.
Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema
Takhzyro (lanadelumab-flyo) is indicated for the preventive treatment of hereditary angioedema (HAE) in patients aged 12 years and older.
Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Cablivi (caplacizumab) is a bivalent anti-Von Willebrand factor (vWF) nanobody indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP).
Will the UK relax its current regulations for cannabis-based products?
Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK home secretary announced that specialist doctors can legally prescribe cannabis-based products in the event of an exceptional clinical need.
CAR-T toxicity rating system to be finalized by ASBMT by year-end
The American Society of Blood and Marrow Transplantation (ASBMT) is in the process of developing a toxicity rating system for CAR-T therapies, a new type of cancer therapeutic approach, for indications like diffuse large B-cell lymphoma (DLBCL) to provide a universal guide in measuring side effects for clinicians, ASBMT President John DiPersio said.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.